


Key points
- CSL’s shares have fallen heavily in 2022
- Citi sees this as a buying opportunity
- The broker expects the acquisition to boost more than just CSL’s near term earnings
The CSL Limited (ASX: CSL) share price is edging lower on Tuesday morning.
At the time of writing, the biotherapeutics giant’s shares are down slightly to $259.86.
This means the CSL share price is now down over 12% since the start of the year.
Is the CSL share price in the buy zone?
According to a note out of Citi from last week, its analysts see a lot of value in the CSL share price at the current level.
The note reveals that its analysts have retained their buy rating and $340.00 price target on the company’s shares.
Based on the current CSL share price, this implies potential upside of 31% over the next 12 months.
What is the broker saying?
Citi has been running the rule over the $7 billion Vifor Pharma acquisition and likes what it sees.
While the acquisition is expected to be accretive to earnings, the broker isn’t as focused on that as others. Instead, Citi sees Vifor Pharma’s complementary research and development (R&D) pipeline as something to get excited about.
In respect to earnings, Citi said: “Because of the large difference in the earnings multiples of both companies and the low cost of debt, we expect the transaction to be double digit NPATA accretive (although ROIC dilutive).”
As for its R&D pipeline, the broker commented: “The key positive from the transaction is that it expands the CSL late stage R&D pipeline, which we have noted for some time was limited for a company the size of CSL.”
And while Citi has a few concerns over “whether this new renal division adds or detracts from the overall CSL strategy,” it isn’t enough to put it off recommending the CSL share price as a buy.
The post Top broker says latest CSL (ASX:CSL) acquisition will boost more than its bottom line. Here’s why appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- 3 ‘champion stocks’ for ASX investors in 2022
- 3 blue chip ASX 200 shares to buy after the selloff
- Own CSL (ASX:CSL) shares? Here’s why the company is moving on from COVID research
- Analysts name 2 beaten down ASX shares with 30% upside
- Can the CSL (ASX:CSL) share price reach pre-COVID highs?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/dq1gCN0tF








